BioSight
Companies
KalVista Pharmaceuticals, Inc. logo

KALV

NASDAQFRAMINGHAM, MA
KalVista Pharmaceuticals, Inc.

KalVista Pharmaceuticals is a biopharmaceutical company focused on developing oral therapies for rare diseases, with its first approved product being EKTERLY (sebetralstat), a small molecule plasma kallikrein inhibitor for treating acute attacks of hereditary angioedema in patients aged 12 and older. EKTERLY received FDA approval in July 2025 and is the first and only oral, on-demand therapy for HAE, with efficacy demonstrated in the phase 3 KONFIDENT clinical trial published in the New England Journal of Medicine in May 2024.

Price history not yet available for KALV.

Pipeline

No pipeline data on record yet.

Catalyst Calendar

No catalyst events on record for yet. Check back after the next daily ingest.

Disclaimer·BioSight aggregates publicly available data (SEC EDGAR, ClinicalTrials.gov, FDA, company press releases) and is provided as is for informational purposes only. Nothing here is investment, financial, legal, tax, or medical advice, or an offer to buy or sell any security. We make no warranty as to accuracy, completeness, or timeliness; dates and filings may contain errors or be superseded without notice; past events do not predict future outcomes. To the maximum extent permitted by law, BioSight, its operators, contributors, and affiliates disclaim all liability for any loss or damage arising from use of or reliance on this site. You are solely responsible for your own investment decisions — consult a licensed professional before acting on any information.

Unlock 12-month calendar